Notice of Results and Investor Presentation

RNS Number : 9840G

IXICO plc

21 November 2022

IXICO plc

("IXICO" or the "Company")

Notice of Results and Investor Presentation

IXICO PLC (AIM: IXI), the medical imaging advanced analysis company delivering intelligent insights in neuroscience, confirms that it will issue its Full Year Results for the year to 30 September 2022 on Wednesday 7^th December 2022.

Giulio Cerroni (CEO) and Grant Nash (CFO) will provide a live presentation relating to their Full Year Results via the Investor Meet Company platform on 7^th December 2022 at 4:30pm GMT.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet IXICO PLC via:

https://www.investormeetcompany.com/ixico-plc/register-investor

Investors who already follow IXICO PLC on the Investor Meet Company platform will automatically be invited.

For further information please contact:

IXICO plc
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer	+44 (0)20 3763 7499

Cenkos Securities PLC (Nominated adviser and sole broker)		+44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Tamar Cranford-Smith (Sales)

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients .

More information is available on www.IXICO.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORBKKBQFBDDDDB

Companies

Ixico (IXI)

Full Archive

UK 100

Latest directors dealings

All directors dealings today